Drug intelligence / Profile preview

nal-irinotecan + 5-fluorouracil + leucovorin + benmelstobart + anlotinib

Development stage: Unknown
Lead developer: Ipsen
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This appears to be a hypothetical combination of five drugs that are not documented as being used together in clinical practice. The individual components have different applications: nal-irinotecan (liposomal irinotecan), 5-fluorouracil, and leucovorin are used in combination for pancreatic cancer, while benmelstobart and anlotinib have been studied together with chemotherapy for small cell lung cancer.

Targets

TOP1 (DNA Topoisomerase I)VEGFR2 (Vascular endothelial growth factor receptor 2)TS (Thymidylate synthase)VEGFR4 (Vascular endothelial growth factor Receptor-3)CD274 (Programmed cell death protein 1 ligand 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR1 (Fibroblast growth factor receptor 1)PDGFRB (Platelet-derived growth factor receptor beta)

Beyond the preview

Go deeper on nal-irinotecan + 5-fluorouracil + leucovorin + benmelstobart + anlotinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nal-irinotecan + 5-fluorouracil + leucovorin + benmelstobart + anlotinib.

Explore the full profile